October 21, 2025
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it…
Pharmaceuticals, Biotechnology and Life Sciences
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it…
Activity Report for Quarter Ended September 30, 2025 (Appendix 4C)NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO;…
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus…
Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS…
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company…
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…
Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed…